ABOLOGIX is one of the winners in Stage I of the Venture Kick competition

Jun 10, 2020

1 min read

Updated: Feb 28, 2025

Geneva, Switzerland, June 10, 2020 – Abologix will receive funding from Venture Kick in order to advance its business development activities and its fundraising efforts.

Abologix obtains funding from the KICK FUND

Geneva, Switzerland, December 23, 2024 – Abologix has been awarded 100,000 CHF by the KICK FUND to progress its advanced preclinical...

Successful completion of the Innosuisse Innovation Project

Geneva, Switzerland, November 23, 2023 – Abologix successfully completes the Innosuisse-funded program for the initial characterization...

Nomination of product H225 as the lead preclinical candidate

Geneva, Switzerland, December 20, 2022 – Abologix nominates monoclonal antibody H225 (blocker of JAM-C, Junction Adhesion Molecule C) as...

ABOLOGIX is one of the winners in Stage I of the Venture Kick competition

Comments

Back to Top